ES2545688T3 - Método de evaluación del riesgo de progresión de enfermedad de pacientes con artritis reumatoide - Google Patents
Método de evaluación del riesgo de progresión de enfermedad de pacientes con artritis reumatoide Download PDFInfo
- Publication number
- ES2545688T3 ES2545688T3 ES07818398.5T ES07818398T ES2545688T3 ES 2545688 T3 ES2545688 T3 ES 2545688T3 ES 07818398 T ES07818398 T ES 07818398T ES 2545688 T3 ES2545688 T3 ES 2545688T3
- Authority
- ES
- Spain
- Prior art keywords
- score
- methods
- risk
- disease progression
- rheumatoid arthritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title abstract description 13
- 206010039073 rheumatoid arthritis Diseases 0.000 title abstract description 5
- 206010061818 Disease progression Diseases 0.000 title abstract description 4
- 230000005750 disease progression Effects 0.000 title abstract description 4
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 3
- 108010074051 C-Reactive Protein Proteins 0.000 abstract 2
- 102100032752 C-reactive protein Human genes 0.000 abstract 2
- 102000004889 Interleukin-6 Human genes 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 229940100601 interleukin-6 Drugs 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000007637 random forest analysis Methods 0.000 abstract 1
- 230000003628 erosive effect Effects 0.000 description 13
- 230000004054 inflammatory process Effects 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 6
- 210000004247 hand Anatomy 0.000 description 6
- 210000001503 joint Anatomy 0.000 description 5
- 210000000707 wrist Anatomy 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 4
- 102000013674 S-100 Human genes 0.000 description 4
- 108700021018 S100 Proteins 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 3
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 3
- 102100032442 Protein S100-A8 Human genes 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 208000008822 Ankylosis Diseases 0.000 description 2
- 206010051728 Bone erosion Diseases 0.000 description 2
- 102100023471 E-selectin Human genes 0.000 description 2
- 101000622123 Homo sapiens E-selectin Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 206010023198 Joint ankylosis Diseases 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 102100032420 Protein S100-A9 Human genes 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000511 carpometacarpal joint Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000003811 finger Anatomy 0.000 description 2
- 210000001145 finger joint Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000001255 hallux Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000000811 metacarpophalangeal joint Anatomy 0.000 description 2
- 210000000878 metatarsophalangeal joint Anatomy 0.000 description 2
- 210000003813 thumb Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- WLSJJMZOYIFPGE-ICHHDKBFSA-N 1,1-difluoro-1-(beta-D-mannosyl)methyl C32-phosphonomycoketide Chemical compound CCCCCCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCCOP(C([C@@H]([C@H]([C@H]1O)O)O[C@H](CO)[C@H]1O)(F)F)(O)=O WLSJJMZOYIFPGE-ICHHDKBFSA-N 0.000 description 1
- IWZOWMVCZCJZJF-ZTZKFORPSA-N 5a-carba-beta-D-mannosyl C32-phosphomycoketide Chemical compound CCCCCCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCCOP(O)(O[C@H](C[C@H](CO)[C@H]([C@@H]1O)O)[C@H]1O)=O IWZOWMVCZCJZJF-ZTZKFORPSA-N 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108010046732 HLA-DR4 Antigen Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102100029812 Protein S100-A12 Human genes 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- 108700028909 Serum Amyloid A Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000029892 regulation of protein phosphorylation Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003189 scaphoid bone Anatomy 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000000623 ulna Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06020645 | 2006-09-29 | ||
| EP06020645 | 2006-09-29 | ||
| EP06021887 | 2006-10-19 | ||
| EP06021887 | 2006-10-19 | ||
| PCT/EP2007/008313 WO2008037420A1 (en) | 2006-09-29 | 2007-09-25 | Assessing the risk of disease progression for a patient with rheumatoid arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2545688T3 true ES2545688T3 (es) | 2015-09-15 |
Family
ID=38859738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07818398.5T Active ES2545688T3 (es) | 2006-09-29 | 2007-09-25 | Método de evaluación del riesgo de progresión de enfermedad de pacientes con artritis reumatoide |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8058013B2 (enExample) |
| EP (1) | EP2074428B1 (enExample) |
| JP (1) | JP2010506147A (enExample) |
| CA (1) | CA2663730A1 (enExample) |
| ES (1) | ES2545688T3 (enExample) |
| WO (1) | WO2008037420A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010038104A1 (en) * | 2008-10-03 | 2010-04-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination of cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event. |
| CA2777800C (en) | 2009-10-15 | 2019-11-12 | Crescendo Bioscience | Biomarkers and methods for measuring and monitoring inflammatory disease activity |
| US20130246097A1 (en) * | 2010-03-17 | 2013-09-19 | Howard M. Kenney | Medical Information Systems and Medical Data Processing Methods |
| JP5786020B2 (ja) * | 2010-04-16 | 2015-09-30 | アボットジャパン株式会社 | 関節リウマチを診断する方法および試薬 |
| WO2012012183A2 (en) * | 2010-06-30 | 2012-01-26 | New York University | Quantifying local inflammatory activity and its use to predict disease progression and tailor treatments |
| JP5924659B2 (ja) * | 2010-10-14 | 2016-05-25 | 国立大学法人 長崎大学 | 免疫複合体の網羅的解析方法および新規関節リウマチバイオマーカー |
| WO2012061821A1 (en) * | 2010-11-06 | 2012-05-10 | Crescendo Bioscience | Biomarkers for predicting progressive joint damage |
| CN105229470B (zh) * | 2013-03-15 | 2018-11-27 | 艾克斯肯诊断股份有限公司 | 用于治疗和诊断系统性红斑狼疮的方法 |
| JP2015061592A (ja) * | 2013-08-21 | 2015-04-02 | コニカミノルタ株式会社 | 超音波診断装置、超音波画像処理方法およびコンピュータ読み取り可能な非一時的な記録媒体 |
| WO2015153437A1 (en) | 2014-04-02 | 2015-10-08 | Crescendo Bioscience | Biomarkers and methods for measuring and monitoring juvenile idiopathic arthritis activity |
| EP3155439A4 (en) | 2014-06-10 | 2018-03-14 | Crescendo Bioscience | Biomarkers and methods for measuring and monitoring axial spondyloarthritis disease activity |
| CA3207751A1 (en) | 2015-09-29 | 2017-04-06 | Laboratory Corporation Of America Holdings | Biomarkers and methods for assessing psoriatic arthritis disease activity |
| WO2017058999A2 (en) | 2015-09-29 | 2017-04-06 | Crescendo Bioscience | Biomarkers and methods for assessing response to inflammatory disease therapy withdrawal |
| GB201603571D0 (en) * | 2016-03-01 | 2016-04-13 | Univ Warwick | Markers for skeletal disorders |
| WO2021087116A1 (en) * | 2019-10-30 | 2021-05-06 | Cd Diagnostics, Inc. | Biomarkers of early osteoarthritis |
| CN114089632B (zh) * | 2021-11-15 | 2023-08-18 | 陕西师范大学 | 基于模糊逻辑的风湿免疫疾病特征识别方法及系统 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9105893D0 (en) * | 1991-03-20 | 1991-05-08 | Orion Yhtymae Oy | Bone resorption assay based on a peptide liberated during collagen degradation |
| US5888510A (en) * | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| ES2154739T3 (es) * | 1994-10-17 | 2001-04-16 | Osteometer Biotech As | Estimacion del modelo de fragmentacion del colageno en fluidos corporales y el diagnostico de trastornos asociados con el metabolismo del colageno. |
| FR2752842B1 (fr) | 1996-08-30 | 1998-11-06 | Biomerieux Sa | Antigenes derives des filaggrines et leur utilisation pour le diagnostic de la polyarthrite rhumatoide |
| NL1004539C2 (nl) | 1996-11-15 | 1998-05-20 | Stichting Tech Wetenschapp | Peptide afgeleid van een door auto-antilichamen van patiënten met reumatoïde artritis herkend antigeen, antilichaam daartegen en werkwijze voor het detecteren van auto-immuunantilichamen. |
| AU2155899A (en) | 1997-11-28 | 1999-06-16 | Innogenetics N.V. | Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment |
| FR2773157B1 (fr) | 1997-12-30 | 2001-10-05 | Bio Merieux | Epitopes peptidiques reconnus par des auto-anticorps antifilaggrine presents dans le serum des patients atteints de polyarthrite rhumatoide |
| CN1284942A (zh) * | 1998-01-09 | 2001-02-21 | 辉瑞大药厂 | 基质金属蛋白酶抑制剂 |
| WO2001046222A2 (en) | 1999-12-21 | 2001-06-28 | Innogenetics N.V. | Peptides designed for the diagnosis and treatment of rheumatoid arthritis |
| NL1019540C2 (nl) | 2001-12-11 | 2003-07-01 | Stichting Tech Wetenschapp | Werkwijze voor het detecteren van auto-antilichamen van patienten die lijden aan reumatoïde artritis, peptide en assaykit. |
| WO2005085859A1 (en) * | 2004-02-27 | 2005-09-15 | Roche Diagnostics Gmbh | Method of assessing rheumatoid arthritis by measuring rheumatoid factor and interleukin-6 |
| US20060063162A1 (en) * | 2004-09-23 | 2006-03-23 | Deng David X | Biological marker for inflammation |
| WO2006098401A1 (ja) * | 2005-03-16 | 2006-09-21 | The University Of Tokushima | 関節リウマチ罹患リスクの測定方法 |
| EP1926747A1 (en) * | 2005-08-12 | 2008-06-04 | Schering Corporation | Mcp1 fusions |
-
2007
- 2007-09-25 ES ES07818398.5T patent/ES2545688T3/es active Active
- 2007-09-25 WO PCT/EP2007/008313 patent/WO2008037420A1/en not_active Ceased
- 2007-09-25 EP EP07818398.5A patent/EP2074428B1/en not_active Not-in-force
- 2007-09-25 CA CA002663730A patent/CA2663730A1/en not_active Abandoned
- 2007-09-25 JP JP2009529589A patent/JP2010506147A/ja active Pending
-
2009
- 2009-03-27 US US12/412,840 patent/US8058013B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010506147A (ja) | 2010-02-25 |
| EP2074428B1 (en) | 2015-07-01 |
| CA2663730A1 (en) | 2008-04-03 |
| WO2008037420A1 (en) | 2008-04-03 |
| EP2074428A1 (en) | 2009-07-01 |
| US8058013B2 (en) | 2011-11-15 |
| US20090270272A1 (en) | 2009-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2545688T3 (es) | Método de evaluación del riesgo de progresión de enfermedad de pacientes con artritis reumatoide | |
| Khella et al. | An evidence-based systematic review of human knee post-traumatic osteoarthritis (PTOA): timeline of clinical presentation and disease markers, comparison of knee joint PTOA models and early disease implications | |
| Denoble et al. | Uric acid is a danger signal of increasing risk for osteoarthritis through inflammasome activation | |
| Chen et al. | Osteoarthritis: toward a comprehensive understanding of pathological mechanism | |
| Stürmer et al. | Severity and extent of osteoarthritis and low grade systemic inflammation as assessed by high sensitivity C reactive protein | |
| Woo et al. | Impact of osteoarthritis on quality of life in a Hong Kong Chinese population. | |
| Punzi et al. | Inflammatory osteoarthritis of the hand | |
| Cuzdan Coskun et al. | Adiponectin: is it a biomarker for assessing the disease severity in knee osteoarthritis patients? | |
| Song et al. | Possible involvement of serum and synovial fluid resistin in knee osteoarthritis: cartilage damage, clinical, and radiological links | |
| Mason et al. | The first tarsometatarsal joint and its association with hallux valgus | |
| Clementi et al. | Efficacy of a single intra-articular injection of ultra-high molecular weight hyaluronic acid for hip osteoarthritis: a randomized controlled study | |
| O'Leary et al. | Characterization of facet joint cartilage properties in the human and interspecies comparisons | |
| Conte et al. | Endothelins modulate inflammatory reaction in zymosan-induced arthritis: participation of LTB4, TNF-α, and CXCL-1 | |
| Ekbote et al. | A descriptive analysis of 14 cases of progressive-psuedorheumatoid-arthropathy of childhood from south India: review of literature in comparison with juvenile idiopathic arthritis | |
| Qin et al. | Expression of NF-κB and osteopontin of synovial fluid of patients with knee osteoarthritis | |
| Galicia et al. | Inflammatory biomarker profiling in total joint arthroplasty and its relevance to circulating levels of lubricin, a novel proteoglycan | |
| Xu et al. | Contributions of joint damage-related events to gout pathogenesis: new insights from laboratory research | |
| Schmal et al. | Early intra‐articular complement activation in ankle fractures | |
| Kamiab et al. | Role of Interleukin-17 family cytokines in disease severity of patients with knee osteoarthritis | |
| Jørgensen et al. | The regional turnover of cartilage collagen matrix in late-stage human knee osteoarthritis | |
| Chu et al. | Cartilage oligomeric matrix protein and matrix metalloproteinase-3 expression in the serum and joint fluid of a reversible osteoarthritis rabbit model | |
| Lambrechts et al. | Comorbidities associated with cervical spine degenerative disc disease | |
| Haider et al. | Plasma and synovial osteopontin levels, are they associated with disease severity of primary knee osteoarthritis in Egyptian patients? | |
| Tachikart et al. | Seno-suppressive molecules as new therapeutic perspectives in rheumatic diseases | |
| Abdel-Magied et al. | Diagnostic potential of ultrasound in systemic lupus erythematosus patients with joint involvement: relation to anticyclic citrullinated peptide (anti-CCP), disease activity and functional status |